Source: Kovo HealthTech
  • Kovo HealthTech (KOVO) has closed its brokered private placement for aggregate gross proceeds of $1,205,000
  • Kovo issued 3,012,500 units at a price of $0.40 per unit
  • Kovo is a leader in healthcare technology and Revenue Cycle Management software and services
  • Kovo HealthTech Corporation (KOVO) is unchanged, trading at C$0.35 per share

Kovo HealthTech (KOVO) has closed its previously announced brokered private placement for aggregate gross proceeds of $1,205,000.

The company issued 3,012,500 units at a price of $0.40 per unit. 

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at a price of C$0.70 for a period of 24 months from the closing date of the offering.

The company expects to use net proceeds for working capital requirements and to fund potential future acquisitions.

The warrants will be subject to early expiration if, at any time prior to the expiry date, the volume-weighted average trading price of the shares on the TSX Venture Exchange is greater than C$1.00 for 10 consecutive trading days.

The placement remains subject to final approval from the TSXV.

The agent received an aggregate cash fee equal to $53,625 and 134,063 non-transferable broker warrants. Kovo is a leader in healthcare technology and Revenue Cycle Management software and services.

Kovo HealthTech Corporation (KOVO) is unchanged, trading at C$0.35 per share.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.